C4 Therapeutics appoints Steve Hoerter, former Deciphera CEO, to board of directors

C4 Therapeutics, Inc.

Steven L. Hoerter appointed as Class II director effective November 19, 2024; serves until 2025 annual meeting.
Hoerter has over 30 years of oncology leadership; was CEO of Deciphera (acquired by ONO for $2.4B).
Granted 65,000 stock options under 2020 Plan; vests 1/3 on first anniversary, remainder quarterly over 2 years.
Board determined Hoerter independent per Nasdaq standards; brings commercialization expertise to guide pipeline.
Hoerter also serves on ORIC Pharmaceuticals board; previously led QINLOCK and TIBSOVO launches.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven L. Hoerter

Director

CCCC · C4 Therapeutics, Inc.

Effective: 2024-11-19
Filed: November 20, 2024, 6:59 PM ET

On November 19 , 2024 , the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven L. Hoerter was appointed as Director at C4 Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 19 , 2024 , the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-048593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.